Evidence map›Paper›PMID 41045485›Full record

ArticleACS chemical biology2025

A Cell-Potent Bisubstrate Inhibitor to Probe NatD Acetyltransferase Activity.

Yi-Hsun Ho, Emma K Seipp, Thitiwat Larndate, Rong Huang

Abstract read
In one paragraph

Article in ACS chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yi-Hsun HoBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.
Emma K SeippBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.
Thitiwat LarndateBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.
Rong HuangBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-1477-3165

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Discovery of small molecule inhibitors for protein N-terminal acetyltransferase DR01CA258887 · NCI · PURDUE UNIVERSITY · PI HUANG, RONG · 2022 to 2025
$2.1M
BD Fortessa Flow Cytometer for Multi-User Shared FacilityS10OD020029 · OD · PURDUE UNIVERSITY · PI RATLIFF, TIMOTHY L. · 2015 to 2015
$412k
NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA258887NIH HHS S10 OD020029
6 · The paper itself

Abstract

N-terminal acetyltransferase D (NatD) is a highly selective enzyme that acetylates the α-N-terminal amine of histones H4 and H2A, which share the SGRGK motif. Elevated NatD expression has been observed in lung, colorectal, breast, and bone cancer tissues, and is correlated with poor patient survival in these cancer types. In non-small cell lung cancer, NatD depletion reduces progression by repressing the epithelial-to-mesenchymal transition (EMT). Hence, NatD is a potential epigenetic target for lung cancer. To unravel the functions of NatD, a cell-potent and selective NatD inhibitor is needed to investigate the acetyltransferase activity of NatD in cancer progression. We previously reported potent and selective NatD bisubstrate inhibitors, designed by covalently linking coenzyme A to peptide substrates via an acetyl and propionyl linker. However, these inhibitors are not cell-active, limiting their application for cellular studies. Here, we designed cell-permeable bisubstrate analogs by attaching cell-penetrating peptides (CPP) to the bisubstrate inhibitor. The inhibitor displayed a

Indexed as

Enzyme InhibitorsN-Terminal AcetyltransferasesAcetylationCadherinsCell Line, TumorEpithelial-Mesenchymal TransitionHistonesHumansLung NeoplasmsVimentinCadherinsEnzyme InhibitorsHistonesN-Terminal AcetyltransferasesVimentin

Identifiers

PMID41045485
PMCPMC12614644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.